๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› HER2-positive Breast Cancer
Clinical trial register · China

HER2-positive Breast Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 7
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing7
All 1 locations
Target enrolment
to

HER2-positive Breast Cancer trials in China

7 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer
NCT06693024HER2-positive Breast Cancer
Shu Wang
Observational
2,806
Beijing
2019-01-01
Recruiting
Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
NCT06722599HER2-positive Breast Cancer
Shu Wang
Observational
171
Beijing
2019-01-01
Recruiting
Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy
NCT06711068HER2-positive Breast Cancer
Shu Wang
Observational
8,077
Beijing
2019-01-01
Recruiting
Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer
NCT06722612HER2-positive Breast Cancer
Shu Wang
Observational
2,916
Beijing
2019-01-01
Recruiting
Adjuvant Therapy Choice for Non-pCR HER2 Positive Early Breast Cancer After Neoadjuvant Therapy
NCT06693037HER2-positive Breast Cancer
Shu Wang
Observational
2,092
Beijing
2019-01-01
Recruiting
De-escalation of Neoadjuvant Chemotherapy Regimens With Targeted Therapy Among HER2 Positive Patients
NCT06700369HER2-positive Breast Cancer
Shu Wang
Observational
519
Beijing
2015-01-01
Recruiting
Taxane Combined Targeted Therapy for Low-risk HER2 Positive and Lymph Node Negative Breast Cancer
NCT06711055HER2-positive Breast Cancer
Shu Wang
Observational
285
Beijing
2015-01-01
Rows per page Showing 1–7 of 7
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/her2-positive-breast-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 7 of those studies listing the condition HER2-positive Breast Cancer that also match the filters currently applied.

How many HER2-positive Breast Cancer trials are recruiting in China?

7 of the 7 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (HER2-positive Breast Cancer), 7 studies
PhaseStudiesRecruitingShare
Observational77100%

Most active sponsors

Lead sponsors with the most studies (HER2-positive Breast Cancer)
Lead sponsorStudiesRecruiting
Shu Wang77
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.